Pankaj Mathur

Pankaj Mathur

Auto-generated profile, based on publicly available information

Pankaj Mathur

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinical Medicine Insights: Cardiology
Verified
Journal Article
Open access
PDF file
PMPankaj Mathur
Pankaj Mathur
SSShweta Srivastava
Shweta Srivastava
XXXiaowei Xu
Xiaowei Xu
Jawahar L MehtaJawahar L Mehta
Jawahar L Mehta
Artificial intelligence (AI)-based applications have found widespread applications in many fields of science, technology, and medicine. The use of enhanced computing power of machines in clinical medicine and diagnostics has been under exploration since the 1960s. More recently, with the advent of advances in computing, algorithms enabling machine learning, especially deep learning networks that mimic the human brain in function, there has been renewed interest to use them in clinical medicine. In cardiovascular medicine, AI-based systems have found new applications in cardiovascular imaging, cardiovascular risk prediction, and newer drug targets. This article aims to describe different AI applications including machine learning and deep learning and their applications in cardiovascular medicine. AI-based applications have enhanced our understanding of different phenotypes of heart failure and congenital heart disease. These applications have led to newer treatment strategies for different types of cardiovascular diseases, newer approach to cardiovascular drug therapy and postmarketing survey of prescription drugs. However, there are several challenges in the clinical use of AI-based applications and interpretation of the results including data privacy, poorly selected/outdated data, selection bias, and unintentional continuance of historical biases/stereotypes in the data which can lead to erroneous conclusions. Still, AI is a transformative technology and has immense potential in health care.

14 August 2015 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
PMPankaj Mathur
Pankaj Mathur
ZDZufeng Ding
Zufeng Ding
TSTom Saldeen
Tom Saldeen
JMJawahar L. Mehta
Jawahar L. Mehta

27 May 2015 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
PMPankaj Mathur
Pankaj Mathur
BOBohuslav Ostadal
Bohuslav Ostadal
FRFrancesco Romeo
Francesco Romeo
Jawahar L MehtaJawahar L Mehta
Jawahar L Mehta

20 December 2016 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
ZDZufeng Ding
Zufeng Ding
SLShijie Liu
Shijie Liu
XWXianwei Wang
Xianwei Wang
PMPankaj Mathur
Pankaj Mathur
YDYao Dai
Yao Dai
JMJawahar L. Mehta
Jawahar L. Mehta
Aims: The present study was designed to investigate a possible interaction between vascular smooth muscle cell (SMC)-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) and mitochondrial DNA (mtDNA) damage. Results: Treatment of cultured SMCs with the proinflammatory stimulus lipopolysaccharide (LPS) stimulated PCSK9 release and induced mtDNA damage. PCSK9 inhibition by its siRNA reduced, and its enhancement increased, mtDNA damage. Induction of mitochondria-derived reactive oxygen species (mtROS) (by rotenone, thenoyltrifluoroacetone, or antimycin A) enhanced mtDNA damage as well as PCSK9 release, suggesting a role of mtROS in PCSK9-mtDNA damage interplay. Induction of mtDNA damage (with the autophagy inhibitor, 3-methyladenine, or DNase II inhibition) enhanced PCSK9 expression, and inhibition of mtDNA damage (with the autophagy inducer, rapamycin) reduced PCSK9 expression, indicating bidirectional interplay between PCSK9 and mtDNA damage. Other studies showed that p38 MAPK is involved in PCSK9-induced mtDNA damage, and mammalian target of rapamycin activation plays a role in mtDNA damage-induced PCSK9 release. Functional impact of PCSK9-mtDNA damage cross-talk was evident in the form of SMC apoptosis, which was enhanced in cells treated with recombinant human PCSK9, but inhibited in cells treated with PCSK9 siRNA. Last, LPS administration in wild-type mice resulted in simultaneous PCSK9 release and mtDNA damage, but mtDNA damage was minimal in PCSK9-null mice given LPS. Innovation: Vascular SMC-derived PCSK9 induces mtDNA damage, and damaged mtDNA fragments stimulate PCSK9 release mediated, at least in part, by mtROS. Conclusions: These observations suggest positive feedback interplay between SMC-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis—a hallmark of atherosclerosis. Antioxid. Redox Signal . 25, 997–1008.

26 May 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
STSharmilan Thanendrarajan
Sharmilan Thanendrarajan
ETErming Tian
Erming Tian
PQPingping Qu
Pingping Qu
PMPankaj Mathur
Pankaj Mathur
CSCarolina Schinke
Carolina Schinke
GMGareth John Morgan
Gareth John Morgan

6 April 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MMMeera Mohan
Meera Mohan
ABAmy Buros
Amy Buros
PMPankaj Mathur
Pankaj Mathur
NGNeriman Gokden
Neriman Gokden
MSManisha Singh
Manisha Singh
CSCarolina Schinke
Carolina Schinke
Light chain deposition disease (LCDD) is characterized by monotypic immunoglobulin depositions which will eventually lead to loss of organ function if left untreated. While the kidney is almost always affected, the presence and degree of LCDD in other organs vary. Ten to thirty percent of LCDD patients have underlying Multiple Myeloma (MM), yet outcome and prognostic markers in this particular patient group are still lacking. Here, we analyzed 69 patients with MM and biopsy proven LCDD and report on renal and extra‐renal involvement and its impact on prognosis as well as renal response depending on hematologic response. Coexisting light chain diseases such as AL amyloid and cast nephropathy were found in 30% of patients; those with LCDD and concurrent amyloid tended to have shorter survival. Cardiac involvement by LCDD was seen in one‐third of our patients and was associated with shorter overall survival; such patients also had a significantly higher risk of treatment‐related mortality (TRM) after stem cell transplant (SCT) compared to LCDD patients without cardiac involvement. This study highlights that MM patients with LCDD present with different clinical features compared to previously reported LCDD cohorts. Rapid initiation of treatment is necessary to prevent progressive renal disease and worse outcome. Coexisting light chain diseases and cardiac involvement are more common than previously reported and confer worse clinical outcome, emphasizing the need for careful patient careful patient evaluation and treatment selection.